Propel Bio Management, LLC
Los Angeles, CA · CIK 1969764 · 13F filing filed 2025-08-13
SEC-registered investment adviser since 2022 · limited liability company
- Assets managed$247.5m
- Staff7 · 6 in investment roles
- Main clients (by assets)Private funds 70%, Mutual funds and ETFs 30%
- Private funds4 (1 hedge) · $172.2m gross assets
- Form ADV · 2026-03-23SEC adviser record
- Legal entityPropel Bio Management LLC (US)
- Kindhedge funds, venture
- Others nearbyLos Angeles, CA
As an employer
- Offices in1 country
- Private fundshedge 1, venture capital 1, other private 2
$82.4m
reported value
-4.3% vs Q1 2025
16positions
97.5%in top 10
2 new
5 added
2 reduced
4 sold out
vs Q1 2025
This report includes the holdings of 1 other manager that shares the investment decisions:
- Simplify Asset Management Inc. – files its own report too; $51.8m of shares are in both
Shares in two reports are counted once in each security's totals.
Holdings, Q2 2025
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| PLAINS GP HLDGS L P PAGP | $24.7m30.01% | Unchanged |
| ACHIEVE LIFE SCIENCES INC ACHV | $13.9m16.88% | Added +3.7m |
| AKERO THERAPEUTICS INC AKRO | $12.2m14.82% | Unchanged |
| PHATHOM PHARMACEUTICALS INC PHAT | $8.9m10.74% | Reduced -212.0k |
| ABEONA THERAPEUTICS INC ABEO | $5.5m6.71% | Added +350.0k |
| APPLIED THERAPEUTICS INC APLT | $3.5m4.26% | Unchanged |
| MILESTONE PHARMACEUTICALS IN MIST | $3.5m4.22% | Added +340.0k |
| DELCATH SYS INC DCTH | $3.1m3.73% | Added +48.5k |
| TSCAN THERAPEUTICS INC TCRX | $3.0m3.67% | Unchanged |
| ZEVRA THERAPEUTICS INC ZVRA | $2.0m2.48% | Added +52.0k |
| CAPRICOR THERAPEUTICS INC CAPR | $695.1k0.84% | New |
| MAAT PHARMA SACA MATPF | $452.1k0.55% | Reduced -72.2k |
| ATHIRA PHARMA INC COM | $450.8k0.55% | Unchanged |
| EIGER BIOPHARMACEUTICALS INC CLDN | $423.0k0.51% | Unchanged |
| WTS - Achieve Life Sci COMM | $13.7k0.02% | New |
| CHINOOK THERAPEUTICS XXX COM | $2.5k0.00% | Unchanged |
Sold out since Q1 2025
| Security | Value then |
|---|---|
| MADRIGAL PHARMACEUTICALS INC MDGL | $9.9m30.0k shares |
| AVIDITY BIOSCIENCES INC RNA | $5.3m178.5k shares |
| SYNDAX PHARMACEUTICALS INC SNDX | $2.3m183.3k shares |
| COMPASS THERAPEUTICS INC CMPX | $433.8k228.3k shares |
Stakes above 5%
Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.
| Company | Stake |
|---|---|
| MILESTONE PHARMACEUTICALS IN MIST · 13G · filed 2025-12-23 | 9.9%≈ $11.9m |